In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to Scholar Rock for its spinal muscular atrophy treatment, and a closer look at the state of evidence linking Tylenol use and autism risk.

In one of the largest recent Medicare fraud cases, Peter Roussonicolos, a Florida durable medical equipment (DME) company owner, was sentenced to 12 years in federal prison for orchestrating a scheme that defrauded Medicare of more than $61 million. Here’s how the scheme worked: Hidden Ownership: Roussonicolos used straw owners to disguise his true role in several DME companies, evading disclosure requirements and regulatory oversight. Illegal Kickbacks: He arranged payments to marketers and...

Send us a text Hi! I am Dr. Akshata Almad, a neuroscientist with over 15 years of experience in understanding neurological diseases including Amyotrophic Lateral Sclerosis, Alzheimer's and Parkinsons disease. I received my PhD in neuroscience from the Ohio State University and have completed her post-doctoral training at Johns Hopkins University. I am currently dedicated to developing innovative therapeutics in drug discovery. In this episode, I share the personal story of my father, w...

In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the FDA’s complete response letter to Otsuka and Lundbeck’s sNDA for Rexulti, and the medical community’s response to former President Trump’s claims linking Tylenol use to autism risk.

Learn the various ways stem cells and other regenerative medical procedures are used in healthy aging treatments.

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.

The FDA has recently stepped up its enforcement of pharmaceutical advertising rules, issuing 100 cease-and-desist notices and thousands of letters. These notices were largely non-personalized and intended as general guidance, emphasizing that drug advertisements must not create misleading impressions. While such enforcement has always been possible, this renewed effort signals increased regulatory attention, particularly on direct-to-consumer marketing. Historically, FDA enforcement letters h...

This week’s tHEORetically Speaking News Roundup covers the CDC’s ACIP meeting and its implications for U.S. vaccine policy, GHO Capital’s acquisition of AI-powered R&D platform Scientist.com, and GSK’s $30 billion investment in U.S. drug manufacturing. We also explore Eli Lilly’s promising pediatric trial results for Mounjaro in type 2 diabetes and several upcoming FDA decisions poised to reshape the pharmaceutical landscape. Tune in for this concise recap of these pivotal industry upda...

Friedemann Zenke’s 2019 paper, and its related coding tutorial SpyTorch, made it possible to apply modern machine learning to spiking neural networks. The innovation reinvigorated the field.

In this episode, we explore why conforming to people's expectations has never saved anyone's soul. [0.01] Introduction[0.43] Chelle reads the storybook[1.16] Evie guides listeners through the too Shake It Off [2.35] Outro This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit michellemcquaid.substack.com

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.

In this episode of STBYM’s The Monstrefact, Robert discusses the Neuralian Mugatos of Star Trek… See omnystudio.com/listener for privacy information.

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.